Table 1.

Characteristics of patients

PatientSexAge, yTreatmentWBC count, × 109/LRai stageCD38Interphase cytogenetics*
1 M 55 None 20 1 NA
2 M 85 Chlorambucil 68 3/4 NA NA
3 M 47 Multiple 40 1 Normal
4 NA NA NA NA NA NA NA
5 F 70 None 60 0 NA NA
6 M 47 None 30 1 NA
7 F 54 Chlorambucil§ 16 0 + +12 13q
8 M 57 None 200 1 NA 13q
9 M 50 None 37 1 NA NA
10 M 75 Multiple 100 3/4 13q
11 M 61 None 69 1 + 13q 11q
12 F 79 Multiple 34 1 NA NA
13 F 69 None 107 1 + Normal
14 M 52 Fludarabine# 200 2 + Normal
15 F 52 None 42 1 NA NA
16 F 57 None 300 1 + +12 t(1;6)
17 M 75 Multiple** 21 2 + 13q
18 F 57 None 219 1 13q 6q
19 F 56 None 72 1 + +12
  • WBC indicates white blood cell; NA, information not available.

  • * The only patients from which variable heavy chain (VH) gene mutational status was available were patients 8 and 10, both having VH unmutated

  • Rituximab, cyclophosphamide, vincristine, and prednisone (2000)

  • Patient 4 entered the study in condition of anonymity

  • § Treatment received in 2003 and 2004

  • Fludarabine/mitoxantrone (1999); cyclophosphamide, vincristine, and prednisone/rituximab (2003); alemtuzumab (2003)

  • Chlorambucil (1992–2000); rituximab, cyclophosphamide, vincristine, and prednisone (2002)

  • # Treatment received in 2001

  • ** Pentostatin/cyclophosphamide/rituximab (2003 and 2004)